nach oben

Erschienen in:

01.12.2012 | Breast

Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review

verfasst von: R. Prevos, M. L. Smidt, V. C. G. Tjan-Heijnen, M. van Goethem, R. G. Beets-Tan, J. E. Wildberger, M. B. I. Lobbes

Erschienen in: European Radiology | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To assess whether magnetic resonance imaging (MRI) can identify pre-treatment differences or monitor early response in breast cancer patients receiving neoadjuvant chemotherapy.

Methods

PubMed, Cochrane library, Medline and Embase databases were searched for publications until January 1, 2012. After primary selection, studies were selected based on predefined inclusion/exclusion criteria. Two reviewers assessed study contents using an extraction form.

Results

In 15 studies, which were mainly underpowered and of heterogeneous study design, 31 different parameters were studied. Most frequently studied parameters were tumour diameter or volume, K^trans, K_ep, V_e, and apparent diffusion coefficient (ADC). Other parameters were analysed in only two or less studies. Tumour diameter, volume, and kinetic parameters did not show any pre-treatment differences between responders and non-responders. In two studies, pre-treatment differences in ADC were observed between study groups. At early response monitoring significant and non-significant changes for all parameters were observed for most of the imaging parameters.

Conclusions

Evidence on distinguishing responders and non-responders to neoadjuvant chemotherapy using pre-treatment MRI, as well as using MRI for early response monitoring, is weak and based on underpowered study results and heterogeneous study design. Thus, the value of breast MRI for response evaluation has not yet been established.

Key Points

• Few well-validated pre-treatment MR parameters exist that identify responders and non-responders.

• Eligible studies showed heterogeneous study designs which hampered pooling of data.

• Confounders and technical variations of MRI accuracy are not studied adequately.

• Value of MRI for response evaluation needs to be established further.

Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97:188–194PubMedCrossRef

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1–22PubMedCrossRef

Chagpar AB, Middleton LP, Sahin AA et al (2006) Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumour size in patients treated with neoadjuvant chemotherapy. Ann Surg 243:257–264PubMedCrossRef

Hylton NM, Blume JD, Bernreuter WK et al (2012) Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy—results from ACRIN 6657/I-SPY TRIAL. Radiology 263:663–672PubMedCrossRef

Yuan Y, Chen XS, Liu SY, Shen KW (2010) Accuracy of MRI in prediction of pathologic complete response in breast cancer after preoperative therapy: a meta-analysis. Am J Roentgenol 195:260–268CrossRef

Cheung Y, Chen S, Su M et al (2003) Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Canc Res Treat 78:51–58CrossRef

Pickles MD, Lowry M, Manton DJ, Gibbs P, Turnbull LW (2005) Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Canc Res Treat 91:1–10CrossRef

Nagashima T, Sakakibara M, Nakamura R et al (2006) Dynamic enhanced MRI predicts chemosensitivity in breast cancer patients. Eur J Radiol 60:270–274PubMedCrossRef

Yu HJ, Chen J, Mehta RS, Nalcioglu O, Su M (2007) MRI measurements of tumour size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy. JMRI 26:615–623PubMedCrossRef

10.

Ah-See M, Makris A, Taylor NJ et al (2008) Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 14:6580–6589PubMedCrossRef

11.

Loo CE, Teertstra HJ, Rodenhuis S et al (2008) Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. AJR Am J Roentgenol 191:1331–1338PubMedCrossRef

12.

Baek H, Chen J, Nie K et al (2009) Predicting pathologic response to neoadjuvant chemotherapy in breast cancer using ¹H MR spectroscopy. Radiology 251:653–662PubMedCrossRef

13.

Park SH, Moon WK, Cho N et al (2010) Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 257:56–63PubMedCrossRef

14.

Li SP, Taylor NJ, Makris A et al (2010) Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy. Radiology 257:643–652PubMedCrossRef

15.

Uematsu T, Kasami M, Yuen S (2010) Neoadjuvant chemotherapy for breast cancer: correlation between the baseline MR imaging findings and responses to therapy. Eur Radiol 20:2315–2322PubMedCrossRef

16.

Wang X, Peng W, Tan H, Xin C, Mao J (2010) Evaluation of dynamic contrast-enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Chin-Ger J Clin Oncol 9:637–642CrossRef

17.

Yu Y, Jiang Q, Miao Y et al (2010) Quantitative analysis of clinical dynamic contrast-enhanced MR imaging for evaluating treatment response in human breast cancer. Radiology 257:47–55PubMedCrossRef

18.

Fan B, Wang X, Yang X, Zhong H, Wu C, Jiang X (2011) Blood oxygen level-dependent MRI for the monitoring of neoadjuvant chemotherapy in breast carcinoma: initial experience. Magn Reson Imag 29:153–159CrossRef

19.

Fangberget A, Nilsen LB, Hole KH et al (2011) Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol 21:1188–1199PubMedCrossRef

20.

Li X, Cheng L, Liu M et al (2012) DW-MRI ADC values can predict treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Med Oncol 29:425–431PubMedCrossRef

21.

McLaughlin R, Hylton N (2011) MRI in breast cancer therapy monitoring. NMR Biomed 24:712–720PubMed

22.

Tofts PS, Kermode AG (1991) Measurement of the blood–brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17:357–367PubMedCrossRef

23.

O’Connor JPB, Jackson A, Parker GJM, Jayson GC (2007) DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96:189–195PubMedCrossRef

24.

Zwick S, Brix G, Tofts PS et al (2010) Simulation-based comparison of two approached frequently used for dynamic contrast-enhanced MRI. Eur Radiol 20:432–442PubMedCrossRef

25.

Woodhams R, Ramadan S, Stanwell P et al (2011) Diffusion-weighted imaging of the breast: principles and clinical applications. Radiographics 31:1059–1084PubMedCrossRef

26.

Esteva FJ, Hortobagyi GN (2008) Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer? J Natl Canc Inst 100:521–523CrossRef

27.

Bear HD, Anderson S, Brown A et al (2003) The effect of tumour response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165–4174PubMedCrossRef

28.

Smith IC, Heys SD, Hutckeon AW et al (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20:1456–1466PubMedCrossRef

29.

Von Minckwitz G, Kummel S, Vogel P et al (2008) Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 100:552–562CrossRef

30.

Von Minckwitz G, Kummel S, Vogel P et al (2008) Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Canc Inst 100:542–551CrossRef

31.

Wu L, Hu J, Gu H, Hua J, Chen J, Xu J (2012) Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy on patients with breast cancer? Breast Cancer Res Treat 135:17-28

32.

Sardanelli F, Boetes C, Borisch B et al (2010) Magnetic resonance imaging of the breast: recommendations from the EUSOMA work group. Eur J Cancer 46:1296–1316PubMedCrossRef

33.

Mann RM, Kuhl CK, Kinkel K, Boetes C (2008) Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol 18:1307–1318PubMedCrossRef

Titel: Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review
verfasst von: R. Prevos
M. L. Smidt
V. C. G. Tjan-Heijnen
M. van Goethem
R. G. Beets-Tan
J. E. Wildberger
M. B. I. Lobbes
Publikationsdatum: 01.12.2012
Verlag: Springer-Verlag
Erschienen in: European Radiology / Ausgabe 12/2012
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-012-2653-5

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review